



July 19, 2006

## **Advisory: Nektar Sets Announcement Date and Conference Call for the Second Quarter 2006**

SAN CARLOS, Calif., Jul 19, 2006 (BUSINESS WIRE) -- Nektar Therapeutics (Nasdaq:NKTR) will announce its financial results for the second quarter 2006 on Thursday, August 3, 2006. On that day, Robert Chess, Nektar chairman of the board and acting president and chief executive officer, will host a conference call for analysts and investors beginning at 2:00 p.m. Pacific Time, to discuss further the Company's performance.

Investors can access a live audio-only webcast through a link that is posted on the Investor Relations section of Nektar's website at <http://www.nektar.com>. The web broadcast of the conference call will be available for replay through August 17, 2006.

Analysts and investors can also access the conference call live via telephone by dialing (800) 559-9370 (U.S.); (847) 619-6819 (international). The passcode is 15219171 and the host is Mr. Robert Chess. An audio replay will be available shortly following the call through August 17, 2006 and can be accessed by dialing (877) 213-9653 (U.S.); or (630) 652-3041 (international) with a passcode of 15219171. In the event that any non-GAAP financial measure is discussed on the conference call that is not described in the press release, related information will be made available on the Investor Relations page at the Nektar website as soon as practical after the conclusion of the conference call.

Nektar Therapeutics is a biopharmaceutical company that develops and enables differentiated therapeutics with its industry-leading drug delivery technologies, expertise and manufacturing capabilities. Nektar technology and know-how have enabled nine approved products for partners, which include the world's leading pharmaceutical and biotechnology companies. Nektar also develops its own products by applying its drug delivery technologies and expertise to existing medicines to enhance performance, such as improving efficacy, safety and compliance.

SOURCE: Nektar Therapeutics

Nektar Therapeutics  
Joyce Strand, 650-631-3138  
Jennifer Ruddock, 650-631-4954

Copyright Business Wire 2006

News Provided by COMTEX